Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension
- PMID: 38560419
- PMCID: PMC10978361
- DOI: 10.1016/j.ahjo.2022.100190
Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension
Abstract
Introduction: Left heart failure (LHF) is commonly complicated by pulmonary hypertension (PH), increasing morbidity and mortality. The present study aimed to evaluate the prognostic value of inflammatory proteins in LHF with PH (LHF-PH).
Materials and methods: The levels of 65 plasma proteins, analysed with proximity extension assay, were compared between healthy controls (n = 20), patients with LHF-PH (n = 67) comprising both HFpEF-PH (n = 31) and HFrEF-PH (n = 36), and in a LHF subpopulation before and after heart transplantation (HT, n = 19). Haemodynamic parameters were measured using right heart catheterization.
Results: Plasma levels of Interleukin 6 (IL-6) and Pentraxin related protein PTX3 (PTX3) were elevated in LHF-PH vs. controls (p < 0.001), and these decreased after HT compared to before HT (p < 0.001). Plasma IL-6 and PTX3 correlated to elevated NT-proBNP (r = 0.44, p = 0.0002 and r = 0.4, p = 0.0009, respectively). Additionally, IL-6 correlated with mean pulmonary arterial pressure (r = 0.4, p = 0.0009) and mean right atrial pressure (r = 0.51, p < 0.0001). Higher levels of IL-6 and PTX3 were associated with worse survival rates in patients with LHF-PH (Log rank p < 0.01).
Discussion: In patients with LHF-PH, higher plasma levels of IL-6 and PTX3 were associated with worse survival rates. Future larger studies to validate and investigate the direct clinical applicability of IL-6 and PTX3 as potential prognostic biomarkers are encouraged.
Keywords: Biomarkers; Haemodynamics; Heart transplantation; Inflammation; Interleukin 6; Left heart disease; Pentraxin related protein 3.
© 2022 The Authors.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Göran Rådegran reports financial support was provided by Janssen Cilag AB. Göran Rådegran reports financial support was provided by Avtal om läkarutbildningen och forskning, ALF. Salaheldin Ahmed reports a relationship with Janssen Cilag AB that includes: speaking and lecture fees. Abdulla Ahmed reports a relationship with Janssen Cilag AB that includes: speaking and lecture fees. Göran Rådegran reports a relationship with Janssen Cilag AB that includes: consulting or advisory, funding grants, and speaking and lecture fees. Göran Rådegran reports a relationship with Actelion Pharmaceuticals Sverige AB that includes: speaking and lecture fees. Göran Rådegran reports a relationship with Bayer health care that includes: speaking and lecture fees. Göran Rådegran reports a relationship with GlaxoSmithKline that includes: speaking and lecture fees. Göran Rådegran reports a relationship with Nordic infucare that includes: speaking and lecture fees. Dr. Rådegran is, and has been primary-, or co-, investigator in; clinical PAH trials for Acceleron, Actelion Pharmaceuticals Sweden AB, Bayer, GlaxoSmithKline, Janssen, Pfizer, and United Therapeutics, and in clinical heart transplantation immunosuppression trials for Novartis. The companies had no role in the data collection, analysis and interpretation and had no right in disapproving of the manuscript.
Figures




Similar articles
-
Plasma tumour necrosis factor-alpha-related proteins in prognosis of heart failure with pulmonary hypertension.ESC Heart Fail. 2023 Dec;10(6):3582-3591. doi: 10.1002/ehf2.14507. Epub 2023 Sep 29. ESC Heart Fail. 2023. PMID: 37772417 Free PMC article.
-
Elevated plasma WIF-1 levels are associated with worse prognosis in heart failure with pulmonary hypertension.ESC Heart Fail. 2022 Dec;9(6):4139-4149. doi: 10.1002/ehf2.14148. Epub 2022 Sep 9. ESC Heart Fail. 2022. PMID: 36082780 Free PMC article.
-
Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation.ESC Heart Fail. 2023 Aug;10(4):2427-2437. doi: 10.1002/ehf2.14399. Epub 2023 May 28. ESC Heart Fail. 2023. PMID: 37246315 Free PMC article.
-
Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension.Int J Cardiol. 2021 Dec 15;345:68-76. doi: 10.1016/j.ijcard.2021.10.136. Epub 2021 Oct 25. Int J Cardiol. 2021. PMID: 34710494
-
Definitions and diagnosis of pulmonary hypertension.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. J Am Coll Cardiol. 2013. PMID: 24355641 Review.
Cited by
-
Plasma tumour necrosis factor-alpha-related proteins in prognosis of heart failure with pulmonary hypertension.ESC Heart Fail. 2023 Dec;10(6):3582-3591. doi: 10.1002/ehf2.14507. Epub 2023 Sep 29. ESC Heart Fail. 2023. PMID: 37772417 Free PMC article.
-
Role of CD93 in Health and Disease.Cells. 2023 Jul 4;12(13):1778. doi: 10.3390/cells12131778. Cells. 2023. PMID: 37443812 Free PMC article. Review.
-
Plasma VEGF-D and sFLT-1 are potential biomarkers of hemodynamics and congestion in heart failure and following heart transplantation.JHLT Open. 2023 Oct 30;2:100013. doi: 10.1016/j.jhlto.2023.100013. eCollection 2023 Dec. JHLT Open. 2023. PMID: 40144016 Free PMC article.
-
Diagnostic and Prognostic Role of CD93 in Cardiovascular Disease: A Systematic Review.Biomolecules. 2023 May 30;13(6):910. doi: 10.3390/biom13060910. Biomolecules. 2023. PMID: 37371490 Free PMC article.
-
New insights into pulmonary arterial hypertension: interaction between PANoptosis and perivascular inflammatory responses.Apoptosis. 2025 Jun;30(5-6):1097-1116. doi: 10.1007/s10495-025-02086-0. Epub 2025 Feb 20. Apoptosis. 2025. PMID: 39979525 Free PMC article. Review.
References
-
- Aras M.A., Psotka M.A., De Marco T. Pulmonary hypertension due to left heart disease: an update. Curr. Cardiol. Rep. 2019;21(7):62. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous